重大事件
即時報告
8-K
2026-06-23
Silence Therapeutics 更新企業演示簡報 披露業務
AI 繁中摘要
📄 **Silence Therapeutics 發佈最新企業簡報 (8-K 申報)**
Silence Therapeutics plc（納斯達克代碼：SLN）於 2026 年 6 月 23 日向美國 SEC 提交了一份 8-K 表格，主要更新一項投資者關係活動。公司當日發佈了經更新的企業演示簡報（corporate presentation），旨在向市場傳達近期的業務進展及策略方向。該簡報已上載至公司官方網站的「投資者關係」欄目，同步作為本 8-K 的附件 99.1 提供。
根據申報，該演示內容僅作為監管規則下的「公開披露」（Regulation FD）用途，不視為《1934 年證券交易法》第 18 條意義上的「已申報文件」，亦不會自動納入公司其他 SEC 申報中，除非明確引用。換言之，今次披露主要為令所有投資者公平獲取最新資訊，而非正式財務報告或重大事件公告。
**重點摘要**：
- 申報類型：8-K（現行報告）
- 主要事件：更新企業演示簡報，反映業務最新狀況
- 關鍵數字：未提供具體財務數據或業績指引
- 管理層展望：演示簡報中或包含前瞻陳述，但本次 8-K 文本未詳細列出
- 對投資者的潛在影響：公司藉此讓市場了解其研發管線、商業化策略或合作進度，有助投資者掌握近期動態。惟需注意演示內容屬自願性披露，投資者應參考後續正式業績及年報作全面分析。
Silence Therapeutics 為一家專注於 RNA 干擾（RNAi）療法、總部位於英國倫敦的生物科技公司。是次更新或與其核心項目（如針對心血管疾病的 siRNA 藥物）的臨床或監管進展有關，建議投資者自行查閱完整簡報以獲取詳細資訊。 🧬
展開英文正文
8-K 0001479615falsetrue00-00000000001479615dei:AdrMember2026-06-232026-06-2300014796152026-06-232026-06-230001479615us-gaap:CommonStockMember2026-06-232026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2026 Silence Therapeutics plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-39487 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 12 Hammersmith Grove London United Kingdom W6 7AP (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: +44 20 3457 6900 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing 3 ordinary shares, nominal value £0.05 per share SLN The Nasdaq Stock Market LLC Ordinary share, nominal value £0.05 per share* * The Nasdaq Stock Market LLC * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01 Regulation FD Disclosure. On June 23, 2026, the Company issued an updated corporate presentation to reflect certain business updates. The presentation is available in the “Investors” section of the Company’s website at silence-therapeutics.com/investors, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The Company’s website and any information contained on the Company’s website are not incorporated by reference into this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d)Exhibits. Exhibit Number Description 99.1 Silence Therapeutics plc corporate presentation dated June 23, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Silence Therapeutics plc Date: June 23, 2026 By: /s/ Iain Ross Name: Iain Ross Title: Interim Principal Executive Officer and Chairman of the Board of Directors (Principal Executive Officer)